Aperture and Verdant Nature
Partnership plan, October 2026

The consumer brand for BioSNEDS, built together.

Aperture takes BioSNEDS to consumers through a subscription-first brand and Amazon. The founders fund it and run it. Verdant supplies the science, earns on every unit from the first sale through ingredient margin and a 5% royalty, and owns 10% of Aperture from signing. The goal beyond that: $200M a year by year 5, then a sale once Aperture is a nine-figure brand with exclusive consumer rights to BioSNEDS.

Revenue goal, Nov 2028$2M / month

Verdant profit at the goal$2.2M / year

Revenue goal, year 5$200M / year

What Verdant earns from Aperture each year

Ingredient margin plus royalty. Live from the model below.

At a glancePlan of record, live

8 products5 singles, 3 blends

Dec 1, 2026Soft launch

Jan 1, 2027Full marketing push

$140kFounder capital, no outside investors

Month 4EBITDA positive

3.0xLTV : CAC at scale

$1.2MVerdant profit in 24 months

Share of US supplement sales at the goal

Market

A $74 billion market BioSNEDS can reach through one brand.

Today BioSNEDS reaches consumers through other companies' products. A consumer brand puts it directly in front of the three in four American adults who already take supplements, starting where demand is moving fastest: GLP-1 support, cellular health and healthy aging, and established nutrients that are hard to absorb.

$74.15BUS supplement sales in 2025, up from $69.3B in 2024. NBJ projects about $87B by 2028.Nutrition Business Journal

75%of US adults use dietary supplements.CRN Consumer Survey, 2024

1 in 8US adults currently take a GLP-1 drug, double the 6% of May 2024. Among adults 50 to 64 it is 22%.KFF Health Tracking Poll, Nov 2025

$346MNAD+ precursor supplement sales in 2025, up 34.8%, projected to reach $557M by 2027.Nutrition Business Journal, via SupplySide

$13.2BUS herbal supplement sales in 2024, up 5.4%. Turmeric sold $141.8M in mainstream retail alone.American Botanical Council, 2025

What it means for the partnership

GLP-1 SupportBuilt for a group of consumers that doubled in about 18 months and is concentrated in the 50 to 64 age band.

NADPro and ResveratrolEnter cellular health and healthy aging, one of the fastest-growing supplement segments.

CoQ10, Curcumin, Berberine, AstaxanthinEstablished categories with known demand, where absorption is the clearest point of difference.

A small share is enoughAt the revenue goal, Aperture's annual run rate is about of US supplement sales.

Competition

Premium, expert-led supplement brands are being valued in the billions.

In August 2026, Procter & Gamble agreed to buy Thorne for about $3.8 billion, roughly six times the $680 million L Catterton paid to take it private in 2023. Thorne's revenue passed $500 million in 2025. Aperture is built for that space: a focused, doctor-led line with BioSNEDS in every product.

Who we compete with, and how Aperture compares

ThorneCategory leaderBroad premium line trusted by practitioners and athletes. Revenue above $500M in 2025; P&G agreed to acquire it for about $3.8B in August 2026.Aperture: the same doctor-led trust, in a focused line where every product uses BioSNEDS.

MomentousPremium, expert-led DTCPerformance supplements sold direct and through expert partners. Took a $32M minority investment from Humble Growth and said in 2025 it was on track to pass $80M in revenue.Aperture: the same expert-led, direct-to-consumer model, applied to absorption.

The Absorption CompanyAbsorption-led DTCFounded by Ian Somerhalder and Nikki Reed. Liposomal powders for restore, energy, calm and sleep, launched through Erewhon in 2024.Aperture: the closest positioning. We lead with single ingredients in small capsules, per-ingredient absorption data from Verdant, and Verdant's physicians.

Sports ResearchAmazon and retail leaderRanked first among Amazon third-party sellers by estimated revenue in April 2026.Aperture: competes on Amazon with channel-specific products and a clear absorption story, against the benchmark for price, reviews and ad efficiency.

QunolCoQ10 specialistOwned by Sanofi since 2023. Its listings lead Amazon's CoQ10 category by estimated monthly units.Aperture: Aperture CoQ10 competes with it directly.

Cata-KorNAD+ specialistLiposomal NAD+ sold on Amazon and TikTok Shop; rebranded from Reus Research in 2025.Aperture: NADPro competes with it directly.

Many smaller brands compete product by product in berberine, curcumin, astaxanthin and sleep, mostly on Amazon. Revenue and ranking figures for private companies are reported or third-party estimates.

Launch lineup

Eight launch products from ten BioSNEDS powders.

Five single-ingredient products and three blends, each a 30-day supply, usually one small capsule a day. The line leads with nutrients that already sell in volume and adds blends for GLP-1 support and sleep, so each product becomes a recurring order for its BioSNEDS powders.

Product · what it's for · BioSNEDS ingredients, active per servingAbsorption vs. standard

Absorption multiples are Verdant Nature's figures; some come from lab permeability models rather than human pharmacokinetic studies. They inform positioning and stay off packaging and ads until the human data behind each one is confirmed.

Brand

A consumer brand built around BioSNEDS.

An aperture controls how much light gets through. The name carries the BioSNEDS story: the dose that matters is the amount the body takes in, so a smaller dose can do more.

Positioning

A luxury-looking brand at a reasonable price, with products that work. We sell efficiency: a smaller dose that does more, backed by Verdant's science and the doctors who use it.

Voice

Calm, precise and plain-spoken. We explain the mechanism simply, cite our sources, and never promise more than structure-function claims allow.

Look and pack

Inspired by Aesop and The Ordinary: amber PET bottles and spare, typographic labels. Singles come in light amber with a white cap and a white label. Blends come in dark amber with a black cap and a black label. One system across all eight products, so the line reads as a set.

Singles: light amber, white cap, white label with black textBlends: dark amber, black cap, black label with white text

Why we win

BioSNEDS at the center. Every product is built on Verdant's delivery technology, developed hand in hand with Verdant.
Doctor-led trust. Verdant's physicians and KOLs, including Dr. Jason Mitchell, front our education and ads.
Recurring revenue by design. Subscription-first on our own store, with multi-month plans that fund growth up front.
An operating team that already does this. Growth, retention, site, creative and supply chain run in-house from day one.

Where the line goes next

Expansion singles already available as BioSNEDS powders: tributyrin, omega DHA and EPA, hyaluronic acid, black seed, BCP and ellagic acid.
Blends that earn a place: Calm (BCP and apigenin), Joint (curcumin and hyaluronic acid) and Glow (astaxanthin and hyaluronic acid).
Custom BioSNEDS conversions and formulations made only for Aperture.

The stories we'll tell, with Verdant

Less is moreA smaller dose the body can use, with no need to overdose. Carl Germano's "Overdosed" article is the starting point.

Compare the doseSide-by-side comparisons of our dose with conventional and liposomal products that recommend standard doses.

See it disperseA simple water test, side by side with conventional and liposomal capsules, filmed for ads with Verdant's team.

Go to market

Subscriptions on our store, profitable volume on Amazon.

Both channels open together, and both reorder BioSNEDS on a regular cycle. Each sells its own channel-specific product codes, so Amazon's price rules never touch the subscription offer.

The subscription offer (our store)

Prices shown at the line's average list price of per 30-day supply. The multi-month plans are the default selection on the product page, which is what lifts first-order value. This structure is the plan of record and gets A/B tested in the first 90 days. Every renewal also carries a loyalty perk, about per order, which raises the share of subscribers who stay at each later renewal by and lifts subscriber value above 3x the cost to win one.

Channels

Our store (Shopify)Subscription only. Growth from whitelisted Meta ads run through Verdant-affiliated doctors' accounts, the Verdant doctor network, and affiliates.

AmazonOne-time purchase, run on PPC for profitable volume. Launch with Vine reviews and 300 to 400 units per product at FBA.

Practitioners and specialty retailTargeted outreach to clinicians who already recommend these nutrients.

TikTok Shop, laterA sampling and awareness channel, kept small.

Timeline

By Nov 20, 2026Inventory produced and received at Amazon FBA; listings live within 7 to 10 days.

Dec 1, 2026Soft launch on both channels at about $10k per month in media.

Jan 1, 2027Full marketing push. Spend reaches about $1k a day by February.

Months 1 to 3Test offers and creative at low spend; learn real acquisition cost and month-two retention.

Months 6 to 9Review cohorts, set the payback rule, then scale only what clears it.

Nov 2028Target: $2M in monthly revenue.

Financial model · 24 months, monthly

What it takes to reach the goal, and what Verdant earns along the way.

A month-by-month plan for the first 24 months. Pick a scenario or change any assumption and every number updates, including Verdant's profit and the value of its stake. Terms are explained below the charts.

Monthly revenue by channel

Our store (subscriptions)Amazon

Select a month to open its full detail.

Profit before marketing subtracts product cost, the Verdant royalty, fulfillment, payment processing and Amazon fees. Founder-contributed services (growth, retention, site, design and creative) are carried at $0. Ingredient purchases are paid on Verdant terms; packaging and fill are paid when ordered. Meta ads are paid one month later on card, then on Meta's monthly invoicing above $50k a month.

What the terms mean

Cost to win a subscriber (CAC): Ad spend divided by the new store subscribers it brings in. It rises as spend grows, from about $55 at launch to $85 at the goal in the base plan.
Subscriber value (LTV): The profit a subscriber produces over time, after product, shipping and fees.
Value vs. cost (LTV:CAC): Subscriber value over 36 months divided by the cost to win that subscriber. 3x or more is the usual mark of a healthy subscription business.
Months to earn back: How many months of a subscriber's orders it takes to repay the cost of winning them.
Profit (EBITDA): Earnings before interest, taxes, depreciation and amortization: revenue minus every operating cost, including ads.
Amazon ads as % of sales (TACoS): Amazon ad spend divided by all Amazon sales. It falls as listings earn reviews and organic rank.
Revenue per ad dollar: All revenue divided by all ad spend in a month.
Founder funding: Cash the founders put in, including a cash reserve kept in the bank. The rest of the growth is paid for by the business.
Net terms: Days Aperture has to pay Verdant for ingredients after they ship.

Years 3 to 5

Profitable growth to $200M a year, then a sale.

After the first 24 months, Aperture scales on three fronts at once: deeper on Amazon, wider direct to customers, and into major retail. The goal is $200M in yearly revenue by year 5 while staying profitable, and a sale once Aperture is a nine-figure brand that holds the US consumer rights to BioSNEDS.

Revenue in year 5 (Dec 2030 to Nov 2031)

Profit (EBITDA) in year 5

Cash to Verdant over five years, from ingredient margin, royalties and the technology purchase

Verdant's 20% at a sale in year 5

Yearly revenue by channel

Our storeAmazonRetailBase case, total

Verdant's cash each year

Verdant's cash stays above its $1.8M a year need once Aperture is at scale.

Ingredient margin, the royalty until the technology purchase, then the purchase payments. Year 3 carries the purchase, paid over the months after closing, so Verdant's cash does not dip when the royalty ends.

How we get there

AmazonGrow from the launch eight to the full line, with bundles and Subscribe & Save, holding Amazon ads near 12% of Amazon sales.

Direct to customersNew products from Verdant's pipeline, practitioner and affiliate programs, and the scientific advisory board leading education.

Retail, from year 3Natural and specialty stores first, then national grocery, mass and drug chains, with retail-specific packs.

The exit

A sale at nine figures in revenueWith the US consumer rights to BioSNEDS, Aperture is the only consumer brand built on the technology, which is what a strategic buyer pays for.

Verdant sells alongside the foundersVerdant's 20% sells on the same terms as the founders' shares, on top of five years of cash from the partnership.

Verdant stays the manufacturerThe supply relationship continues after the technology purchase and after a sale.

Risks

What has to be true, and how we'll know early.

Three assumptions carry most of the plan. Each is tested in the first 90 days at low spend. The figures show the plan if one of them misses, and they follow the model above.

Two more we manage with Verdant

Absorption claimsSome multiples come from lab permeability models rather than human pharmacokinetic studies. They stay off packaging and ads until the human data behind each one is confirmed.

Supply at scaleAt the goal the line needs about of BioSNEDS powder a month. Capacity commitments, lead times and safety stock for likely hero products are part of the ask below.

Team

Two founders who run the whole operation.

The founders fund the launch from existing business cash flow, with no outside investors and no raise planned. Growth and operations run in-house from day one.

Conor Itaya

Brand, growth and digital. Runs brand, site, retention, creative and paid media, and Amazon through a dedicated Amazon team.

Chris "Bernie" Bernard

Product and operations. Runs product development, manufacturing and supply chain, and brought the Verdant relationship.

Scientific advisory board

Five seats, formed with Verdant. Dr. Jason Mitchell is the first. The board reviews formulations and claims and fronts our education.

Partnership

What the partnership is worth to Verdant.

Verdant earns twice on every unit: margin on the BioSNEDS powders it supplies, and a 5% royalty on Aperture's sales from the first sale. The founders carry the launch costs and the risk. These figures follow the model above, so they move with every assumption.

Verdant profit over 24 months, from ingredient margin and royalties.

Verdant profit per year at the goal, against a $1.8M a year goal

Paid to Verdant over 24 months, in royalties and ingredient purchases

BioSNEDS powder needed per month at the target, about units

Cash flow now, equity that builds

Verdant's stake grows in value once Aperture holds the US consumer rights.

Monthly profit to Verdant

Ingredient margin (paid on net terms)Royalty

Ingredient orders by BioSNEDS powder, by quarter

Orders are placed ahead of sales to hold three months of inventory, so they lead the revenue curve. Each of the eight products is assumed to be an equal share of bottles until we have real sell-through; dollar figures use the powder prices in our current cost model, so Verdant can apply its own margin per ingredient.

Verdant Nature

BioSNEDS ingredients and the science behind them
Custom conversions and formulations for Aperture
Physicians, KOLs and clinical support for education and ads
Help forming a five-person scientific advisory board

The founders

Launch working capital
Brand, site, retention, creative and paid media
Amazon operations
Product development, manufacturing and supply chain, led by Bernie

To plan together

Maximum monthly output per BioSNEDS powder, and lead times
Safety stock for the likely hero products
Backup sourcing if a raw material tightens
Clinical and PK data to support claims

The proposal

Four parts, signed together.

Verdant earns cash from the first sale, owns 10% of Aperture from signing, and moves to 20% once Aperture holds the US consumer rights to BioSNEDS. Each part grows as Aperture grows.

Supply agreement

Five years of BioSNEDS supply, at Verdant's normal margin.

Verdant keeps its normal margin on every ingredient, with no free or at-cost runs. Pricing can improve as bulk orders grow.
Phased US consumer exclusivity: existing customers stay, no new consumer brands that compete with Aperture, moving to full exclusivity on milestones we set together.
Payment terms start at net 60 and move to net 90 as volume grows.
Verdant keeps BioSNEDS for non-consumer uses such as pharmaceutical and animal health.

Royalty

5% of Aperture's net sales, from the first sale.

Paid on top of ingredient purchases, so Verdant earns twice on every unit, until Aperture buys the US consumer rights. Then it ends.
Verdant is the only partner with a royalty. The founders take no cash out; profit goes back into growth.
In the plan: over the first 24 months, running at a year by the end of year 2.

Equity

10% of Aperture at signing, rising to 20%.

The first 10% vests as Verdant delivers exclusivity, custom formulations, clinical support and KOL promotion.
A further 10% when Aperture takes the US consumer rights to BioSNEDS, keeping Verdant invested after the rights change hands.
In the plan: 10% is worth about at the goal, and 20% with exclusive rights about .
Non-voting units with full economic rights. Verdant sells alongside the founders, on the same terms, in any sale of Aperture.

Technology option

Aperture may buy the US consumer rights to BioSNEDS once sales pass $20M a year.

Price: 5x Verdant's royalty over the prior 12 months, paid in cash at closing.
The royalty ends at closing. Verdant's stake rises to 20%, and it keeps its ingredient margin as Aperture's manufacturing partner.
Verdant keeps BioSNEDS for every non-consumer use.
In the plan:

What protects Verdant

A floor on the technology price

An exclusive license; Verdant keeps the patentsAperture takes an exclusive, perpetual license to the US consumer rights. Verdant keeps the patents, the BioSNEDS name and every other use.

If Aperture is soldThe license and the supply agreement go with the brand, so the buyer keeps Verdant as manufacturer, and Verdant sells its stake on the same terms as the founders.

Equity that keeps its sharePro-rata rights to keep its percentage in any future raise, and the same share of any distributions as the founders.

Full transparencyVerdant sees what we see: live access to Shopify, Amazon, our ad accounts and our financials, a seat in our Slack channels, and rolling 12-month ingredient forecasts for capacity planning.

Why the rights purchase is Verdant's biggest upside

Selling Aperture the consumer rights is worth more to Verdant than keeping the royalty.

A moat buyers pay for. With the US consumer rights, no other consumer brand can build on BioSNEDS. That is what a strategic buyer pays a premium for: the model values Aperture at x profit with the rights and x without.
Twice the stake. Verdant moves from 10% to 20% of a company that is already worth more because of the rights.
Cash for the rights. when the rights change hands, and Verdant keeps its ingredient margin as Aperture's manufacturer.

This page is our full proposal and replaces earlier written versions. Non-binding and subject to definitive agreements. Option price and timing follow the model above.

The ask

Build the consumer brand for BioSNEDS with us.

The founders fund the launch and run the business. We're asking Verdant for the science, supply and guidance behind it.

See next steps

What we're asking Verdant for

A BioSNEDS supply partnership for the full line, on the terms above.
Capacity and lead times for the ten launch powders, with safety stock for the likely hero products.
Clinical and PK data, and review of product and ad claims.
Physician and KOL support, including Dr. Jason Mitchell, for education and ads.
A scientific advisory board: help forming five seats, with Dr. Jason Mitchell as the first member.
Strategic guidance: a regular working session on the formulation roadmap, new conversions and the practitioner channel.

What Verdant gets

in profit over 24 months from ingredient margin and royalties, reaching a year at the goal.
10% of Aperture at signing, rising to 20% when Aperture takes the US consumer rights to BioSNEDS, worth about at the goal.
A consumer brand built entirely on BioSNEDS, run by an operating team that already does this.
Founder capital and founder-contributed services, so the launch needs no cash from Verdant.

Next steps

NowAgree the partnership and confirm capacity and lead times for the first production run.

By Nov 20, 2026Inventory produced and received at Amazon FBA.

Dec 1, 2026Soft launch on both channels.

March 2027First 90-day review together: offer mix, acquisition cost and month-two retention against this plan.